Advertisement

Dynavax Technologies (DVAX) Q2 2020 Earnings Call Transcript

Dynavax Technologies (DVAX) Q2 2020 Earnings Call Transcript

Joining me on the call today are Ryan Spencer, chief executive officer; Michael Ostrach, chief financial officer; Robert Janssen, chief medical officer and senior vice president, clinical development; and Donn Casale, vice president, commercial. Before we begin, I advise you that we will be making forward-looking statements today, including statements regarding HEPLISAV-B's commercial profile, revenue expectations, potential peak revenue, the completion of the post-marketing study, and regarding vaccine development potential with CpG 1018.